Why the study?
What are the current and novel imaging methods for detecting chemotherapy-associated cardiotoxicity and dysfunction?
What are the current and novel imaging methods for detecting chemotherapy-associated cardiotoxicity and dysfunction?
This review highlights the current clinical measures, limitations, and novel imaging techniques for monitoring and detecting chemotherapy-induced cardiotoxicity and cardiac dysfunction.
Current methods have limitations for chemotherapy cardiotoxicity detection; review leaves open validation of novel imaging before clinical adoption.
Survival in cancer has improved, shifting some of the focus of care to minimizing the long term complications of cancer therapy. Cardiovascular disease is a leading long-term cause of morbidity and mortality in patients who survive cancer. In the review we will focus on imaging techniques that are used to detect the cardiovascular consequences of chemotherapy. We will differentiate cardiotoxicity and cardiac injury from cardiac dysfunction and cardiomyopathy. We will discuss the current clinical measures that are used to monitor patients, the limitations of each technique, and then detail research into novel methods for tracking and detecting the cardiac toxicity and cardiac dysfunction that may occur as a result of chemotherapy.
No takes yet. Share an insight, caveat, or question.
Ong et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: